OPEN Health unites patient engagement experts to transform the patient experience
London, Nov. 20, 2023 (GLOBE NEWSWIRE) -- London, UK – November 20, 2023 – OPEN Health, a preeminent global provider of consulting, HEOR and market access, patient engagement, and scientific and creative communications services, is bringing together experts in strategic patient innovation and engagement, deepening the organization's existing commitment to building patient-first solutions.
OPEN Health is combining the strength, expertise, and proven track record of the Px Group, a division of the CM Group which was acquired in 2022, and OPEN Health’s own patient engagement team into a unified global patient communications, patient research, and creative patient engagement partner. The combined team will be led by Cherie Myatt, alongside Senior Vice President Alexandra Dubois, Registered Health Psychologist and Cognitive Behavioral Therapist Dr. Sumira Riaz, and Patient Centricity Global Lead Gavin Jones.
Myatt, co-founder of the CM Group, started to build out a patient engagement team in 2016 based on clients’ needs to connect and activate their patient communities. She and Dubois, an experienced marketer and rare disease advocate, launched a division of the agency focused exclusively on providing patient engagement solutions to clients in the life sciences industry, particularly those in rare and complex conditions. Dr. Sumira Riaz has led OPEN Health’s Patient Engagement practice in Europe for the past six years, with an industry-leading team of health psychologists and behavioral scientists.
“I am excited to bring together our global experts to focus on engagement with patients, caregivers, community leaders, and advocacy groups. Together, we will use the patient voice to improve life-changing treatments across the globe,” said Myatt, whose title is President of OPEN Health Patient Engagement.
Dr. Annemarie Clegg, Chief Medical Officer at OPEN Health, commented, “By working as one, united team, we can better leverage our respective talents and methodologies to unlock patient engagement opportunities across the product life cycle and drive more effective engagement solutions.”
Collaborating with more than 1,300 global OPEN Health experts, the Patient Engagement team provides a wide range of solutions to address specific challenges for clients. Its full suite of solutions includes:
- Strategy, insights & market research – delivers design solutions that resonate with communities and significantly impact disease outcomes with a profound understanding of patient needs.
- Health psychology & behavioral science – delivers comprehensive insights into the lived experience of patient and caregiver with evidence-based methodologies.
- Patient content & storytelling – delivers patient-focused communications and storytelling solutions that educate, connect, and inspire.
- Patient Engager™ programs and advocacy engagement – partners with life sciences companies and their patients and caregiver communities to purposefully infuse the patient perspective into programs and communications.
To learn more, visit https://www.openhealthgroup.com/patient-engagement
About OPEN Health
OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient well-being. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across consulting, HEOR and market access, scientific communications, patient engagement, and creative omnichannel communications. For more information on OPEN Health, visit www.openhealthgroup.com.
Candice Subero, Vice President, Global Marketing
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Fluence Responds to Misleading Short Seller Report22.2.2024 23:32:54 CET | Press release
ARLINGTON, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence” or “the Company”) (NASDAQ: FLNC), a leading global provider of energy storage products, services, and optimization software for renewables and storage, today issued a statement in response to a report published by a known short-seller. The Company believes that the report is an attempt by a self-interested short-seller to profit at the expense of Fluence’s shareholders by manipulating Fluence’s stock price. We believe that the report contains numerous inaccuracies and distortions. The Company believes it is important to set the record straight regarding three blatant misrepresentations: The short-seller's report references pending litigation between Fluence and Siemens Energy, attempting to characterize it as a "critical and dramatic development." While any dispute with a customer is unfortunate, this is a small, ordinary course commercial dispute arising from a single project. Fluence brought the action
Galapagos announces full year 2023 results and outlook for 202422.2.2024 22:01:00 CET | Press release
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, in rrCLL, with or without RTExpanded CAR-T pipeline with start of Phase 1/2 study with BCMA CAR-T product candidate GLPG5301 in rrMMEnrolled first patients in Phase 2 study with TYK2 inhibitor, GLPG3667, in DM and SLEFor strategic reasons, it was decided not to continue development of CD19 CAR-T candidate in rSLEExpanded point-of-care CAR-T network in the U.S. with manufacturing agreements with Landmark Bio and Thermo Fisher Scientific Signed strategic research and license collaboration with Brid
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors22.2.2024 19:02:45 CET | Press release
Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February 22, 2024. At its meeting on February 22, 2024, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors. Diane Souza, Member of the Audit and Compensation Committees, and Thomas Südhof, Chairman of the Scientific Committee, will leave the Board of Directors at the end of their second terms. The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office. The Chairman specified that, in order to prepare as effectively as possible for the end, in 2025, of the term of office as director of F
EVS reports 2023 results22.2.2024 18:30:00 CET | Press release
Publication on February 22, 2024, after market closing Regulated and inside information – Press release annual results EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports 2023 results Liège, Belgium, February 22nd, 2024 EVS further delivers profitable growth in 2023, validating the effectiveness of its PlayForward strategy The robust financial performance of EVS in 2023 underscores the effectiveness of the implemented strategy aimed at fostering sustained and profitable long-term growth. Despite the absence of significant Big Event Rental revenue in an uneven year 2023, EVS achieved record-breaking revenue and demonstrated strong profitability. This success serves as a testament to the efficacy of its PlayForward strategy. Full-year Highlights Order intake outpacing revenue at EUR 192.9 million, including EUR 7.4 million of Big Event Rental (BER).Revenue performance landing north of our guidance at EUR 173.2 million, growing 16.9%
RevoluGROUP Canada Inc. Issues Incentive Share Options22.2.2024 18:23:23 CET | Press release
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the "Company") announces that incentive share options to purchase up to 5,200,000 common shares of the Company were granted to consultants and Directors of the Company, with an exercise price of $0.05 per share. The incentive share options have been granted pursuant to the Company's 10% rolling stock option plan and will expire twenty-four months from the grant date. Should all announced options be exercised in the term, the aggregate amount payable to the treasury would be CA $ 260,000. The options are to be granted as shown below: Francisco Moreno Balboa1,500,000Gavin McMillan500,000Bernard Lonis500,000Alfredo Manresa Ruiz500,000Fernando Guillen Hernandez500,000 An additional 1,700,000 options were also granted to consultants in the Company who have provided valuable assistance in the development of products, business development, solution integra